Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Denali Therapeutics Inc. (DNLI) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-06-30, net income was -511.5m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Denali Therapeutics Inc. (DNLI) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Denali Therapeutics Inc. (DNLI) on October 30, 2026 is 18.95 $, −1.89 % on the day. Over 52 weeks the stock traded between 13.75 $ and 27.30 $; the price now sits 38 % of the way up that range. Over the past year the price changed by +5.32 %. Market capitalization is 3.03 billion $, rank 25 among 132 stocks of the same industry with a known capitalization.
Denali Therapeutics Inc. trades on Nasdaq under the ticker DNLI. The company belongs to the Health care sector. The trading history on this page starts on 8 December 2017.
Over the past 52 weeks DNLI has traded between 13.75 $ and 27.30 $. As of 30 October 2026 the price stood 28.49 % of the way from the 52-week low to the high.
Over one year DNLI shares rose 5.32 %; over six months they fell 14.39 %. Volatility over 90 days is 47.38 %. Dividends are not included: this is price change only, as of 30 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 840, above the sector median of 3.6. Price to book is 3.6, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
DNLI has a return on equity of −61.24 %, below the sector median of −40.58 %. Return on assets is −44.17 %, below the sector median of −30.08 %.